The first lot of IPV will be supplied to the government this month as per the requirement of the Health Ministry
The trial will evaluate the efficacy of psilocybin in Short-lasting Unilateral Neuralgiform Headache Attacks (SUNHA). The data is expected in early 2022
Laurus will be incentivised for a portion of its development and commercialisation costs. CHAI will also provide technical and regulatory support to enable accelerated generic development
Research collaboration covers multiple antibody research programs
The institute will provide the world’s first unique and comprehensive capability to predict, prevent, respond and to recover from future pandemics
Everest gains access to a clinically validated mRNA platform and a potentially “best-in-class” mRNA COVID-19 vaccine with full technology transfer
Crosscope and KFBIO join forces to lead digital transformation for pathology in India and emerging markets
Over 70 per cent of the world’s population have no access to MRI scanners and the situation is not that encouraging in India where there are only 0.4 MRI scanners per thousand people
HTL will build, validate and operate a botulinum manufacturing facility in the US
Nipah virus (NiV) is an emerging zoonotic disease that causes severe disease in humans. Signs and symptoms range from asymptomatic to acute respiratory infection and fatal encephalitis
Subscribe To Our Newsletter & Stay Updated
